Safety and Efficacy Assessment of Pcnl in The Pediatric Population: A Single Centre Experience Volume 3 - Issue 3

Prakash Babu SML, Vivek Meyyappan*, Vivek Jayakumar, Tarun Javali and HK Nagaraj

• Department of Urology, Ramaiah Medical College, India

Received: November 05, 2021;   Published: December 06, 2021

Corresponding author: Vivek Meyyappan, Department of Urology, Ramaiah Medical College, Bengaluru, India

DOI: 10.32474/JUNS.2021.03.000162

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Introduction and Objective: Renal stone disease in children is on the rise with increased incidence and better modalities to diagnose the disease. Hence there is a necessity to strategize the evaluation and treatment of children with kidney stones. Our study was conducted to assess stone distribution, stone burden, and efficacy of PCNL in pediatric age group.
Methods: All paediatric patients with renal stone disease who subsequently underwent PCNL at our department from January 2017 to December 2020 were analysed.
Results: 84 patients ranging 1-18 years were analysed. Pain abdomen was the most common presenting symptom (61.9%) followed by fever (19.04%). The mean stone size was 2.16cm with equal side distribution. Most stones were located in the lower calyx (38%). The mean operative time was 65 minutes. Exposure to radiation from C arm ranged from 1.6-8.3 minutes. Complete stone clearance was achieved in 90.47% with a mean post- drop in Hb value to 0.72 gm/dl. Mean duration of nephrostomy tube in situ was 2.4 days and with a mean hospital stay of 3.8 days. Calcium oxalate was the most common type of stone (48%) Conclusion: PCNL is safe and effective treatment for pediatric renal calculi with minimal morbidity and increased stone free rates irrespective of stone size. Proper patient selection, surgical skill and postoperative care contribute towards the success of the procedure

Keywords: Pediatric PCNL; Pediatric Renal Calculi; Renal Stone Disease

Abstract| Introduction| Materials and Methods| Results| Discussion| Limitations| Conclusion| Financial Disclaimer| Conflict of Interest| Acknowledgement| References|